3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Glioma
3
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Interventions
Cyclophosphamide
2
sargramostim
1
poly ICLC
1
pembrolizumab
1
olaparib
1
lutetium Lu 177 dotatate
1
lorvotuzumab mertansine
1
ixabepilone
1
fludarabine
1
cixutumumab
1
aldesleukin
1
Zoledronic Acid
1
Trabectedin
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Interleukin-2
1
Immunotherapy, Adoptive
1
Immunotherapy
1
Drug Therapy
1
Decitabine
1
CLR1404
1
Biological Therapy
1
Ado-Trastuzumab Emtansine
1
Adjuvants, Pharmaceutic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Synovial
×
CLR1404
×
CNS
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled